Toxic Megacolon After Irrational Antibiotic Treatment of Pregnant Patient With Covid 19: Case Report

Mladen M. Maksić, Andela Ž. Đokić, Nataša D. Zdravković, Biljana N. Milojković - Kicevska, Radiša H. Vojinović, Tijana B. Veljković, Svetlana S. Popović - Matović, Slobodan M. Janković

1 University Clinical Center Kragujevac, Kragujevac, Serbia
2 Faculty of medical Sciences, University of Kragujevac, Kragujevac, Serbia

SUMMARY

Introduction: Optimal management of toxic megacolon as a consequence of Cl. difficile colitis is still matter of controversy, as well as timing of available therapeutic modalities. In this article we report a case of severe C. difficile colitis associated with toxic megacolon in a pregnant patient with Covid 19, who was successfully treated conservatively.

Case Report: A 33-years old pregnant woman contracted SARS-CoV-2 in the 32nd week of pregnancy. She was admitted to regional hospital and treated extensively by wide-spectrum antibiotics. After the delivery she developed severe form of Cl. difficile colitis with toxic megacolon. In spite of severe clinical picture, the patient was treated conservatively, with high initial oral doses of vancomycin, with subsequent tapering. The outcome of the treatment was complete recovery and colonic functions were regained completely.

Conclusion: In conclusion, our case shows that in younger patients, who were fit before occurrence of Cl. difficile colitis and toxic megacolon, conservative therapy should be tried as long as possible before turning to colectomy, since chances for cure without surgery are considerable.

Keywords: Cl. Difficile Colitis, Toxic Megacolon, Vancomycin

INTRODUCTION

Toxic megacolon is life-threatening disease and may be defined as a nonobstructive partial or pan colonic dilatation in excess of 6 cm with signs of systemic toxicity [1,2].

Leading cause of toxic megacolon is Inflammatory bowel disease, but it could be consequence of Clostridium difficile infection, too [3]. Incidence of toxic megacolon after colitis induced by Clostridium difficile is relatively low and ranges from 0.4% to 3%, but the mortality rate is very high, between 38% and 80%, mostly due to colonic perforation followed by peritonitis, septic shock and multiple organ dysfunction [4,5,6]. In hospital settings main reason for Cl. Difficile infection (CDI) is prolonged treatment of patients with broad-spectrum antibiotics. Current COVID 19 pandemics has contributed to this problem.
indirectly, through overzealous administration of antibiotics to patients with COVID 19 and pneumonia, since it is difficult in clinical practice to differentiate between viral and bacterial origin of pneumonia, especially in resource-poor settings [7].

Although clindamycin, cephalosporins and fluoroquinolones are antibiotics the most frequently associated with C. Difficile infection, other broad-spectrum antibiotic are followed by certain percentage of CI. Difficile cases, too [8]. Toxins of C. difficile induce release of proinflammatory cytokines into the colon wall which further increase permeability of blood vessels and cell necrosis [9]. Mourell et al showed induction of inducible nitric oxide (NO) synthetase in the muscularis propria of patients with toxic megacolon [10]. Increased production of NO leads to inhibition of smooth muscle tone and colon becomes dilated [11]. Sudden stopping of diarrhea due to ileus, rapid abdominal distension, abdominal pain and tenderness, tachycardia and hypotension in patients diagnosed with CDI are key signs pointing to emergence of toxic megacolon [12]. The diagnosis of toxic megacolon has to be radiologically confirmed. Computerized Tomography (CT) of abdomen may show at least 6 cm wide dilatation of colon, wall thickening, distortion of haustral folds, and ascites [13]. Optimal management of toxic megacolon is still matter of controversy, as well as timing of available therapeutic modalities [14]. We found only one case report with association toxic megacolon in Covid 19 patient and they tried with antibiotics but main therapy was a surgery,because patient had a perforation of colon [15].

In this article we report a case of severe C. Difficile colitis associated with toxic megacolon in a pregnant patient with Covid 19, who was successfully treated conservatively.

CASE REPORT

The patient was a 33-year-old woman with hypothyroidism on tablets levothyroxine-natrium (Euthyrox®, Merck Healthcare KgaA) 100 mcg / daily, without allergy and previously operation, in well health condition, who in the 32nd week of pregnancy contracted SARS-CoV-2.

She was admitted to regional hospital and treated with broad spectrum antibiot-
omicin (Voxin®, Vianex S.A.-Plant C) 1 g at 24h administered both orally and by an enema, the ampules metronidazole (Orvagil®, Galenika AD Beograd) 500 mg at 8h was given intravenously, and the following drugs were also added intravenously: corticosteroids (metylprednisolon Lemo®-Solu Hemopharm AD Vršac 40 mg/ml intravenously at 24h), human albumin (Albutein 20% Instituto Grifols S.A. 200 g/L intravenously at 8h), diuretics (furosemid Lasix® Opella healthcare international sas 40 mg at 24h per os), neostigmin-metilsulphat (Neostigmine/Cooper, Cooper S.A. 2.5 mg/ml at 24h intramuscular) and packed red cells transfusions with 3 units (one unit 250 mL), haemoglobin (110-180 g/L) transfusion trigger was 80 g/L. She was not treated surgically due to low parameters of inflammation, C reactive protein dropped to 64 mg/l (0-5 mg/L), blood pressure was 100/60 mmHg, patient was transferred to the internal medicine department. The abdomen was extremely enlarged, with circumference of 111 cm at the level of umbilicus. The fever persisted, and the patient developed cellulitis of the lateral parts of anterior abdominal wall. The laboratory showed low haemoglobin (110-180 g/L) from 77 mg/l to 95 mg/l, D-dimer 2,87 µ/mL (0-0.5 µ/mL), albumin (41-51 g/L) from 26 g/l to 39 g/l, C reactive protein (0-5 mg/L), gradually dropped to 39 mg/l, and then to 6.9 mg/l, amylase (40-140 U/L) and procalcitonin (0-0.05 µg/L) became normal. The patient was treated additionally with parenteral vancomycin, while oral administration of vancomycin (Voxin®, Vianex S.A.-Plant C) and ampules metronidazole (Orvagil®, Galenika AD Beograd) 500 mg at 8h was continued. Serum levels of vancomycin (Voxin®, Vianex S.A.-Plant C) were monitored to prevent toxicity. The signs of cellulitis gradually abated, however repeated MDCT showed persistent signs of colonic inflammation: the wall of large intestine was up to 3 cm thick in some parts due to extensive edema, and several inclusions of gas were seen in submucosa. General condition of the patient was improved little by little, as well as her stools. Antibiotic therapy with

After vital functions of the patient became stable, temperature was 37.5 °C, CRP dropped to 45 mg/l (0-5 mg/L), blood pressure was 100/60 mmHg, patient was transferred to the internal medicine department. The abdomen was extremely enlarged, with circumference of 111 cm at the level of umbilicus. The fever persisted, and the patient developed cellulitis of the lateral parts of anterior abdominal wall. The laboratory showed low haemoglobin (110-180 g/L) from 77 mg/l to 95 mg/l, D-dimer 2,87 µ/mL (0-0.5 µ/mL), albumin (41-51 g/L) from 26 g/l to 39 g/l, C reactive protein (0-5 mg/L), gradually dropped to 39 mg/l, and then to 6.9 mg/l, amylase (40-140 U/L) and procalcitonin (0-0.05 µg/L) became normal. The patient was treated additionally with parenteral vancomycin, while oral administration of vancomycin (Voxin®, Vianex S.A.-Plant C) and ampules metronidazole (Orvagil®, Galenika AD Beograd) 500 mg at 8h was continued. Serum levels of vancomycin (Voxin®, Vianex S.A.-Plant C) were monitored to prevent toxicity. The signs of cellulitis gradually abated, however repeated MDCT showed persistent signs of colonic inflammation: the wall of large intestine was up to 3 cm thick in some parts due to extensive edema, and several inclusions of gas were seen in submucosa. General condition of the patient was improved little by little, as well as her stools. Antibiotic therapy with
intravenous vancomycin and oral metronidazole was discontinued after 3 weeks, and oral vancomycin (Voxin®, Vianex S.A.-Plant C) 1 g at 24h was continued with tapering doses for further 5 weeks.

The patient was discharged after 46 days of hospitalization for further home treatment when an additional MSCT showed signs of mild intestinal distension. She continued taking oral vancomycin (Voxin®, Vianex S.A.-Plant C) at home with tapered doses until 8 weeks from the beginning of oral vancomycin (Voxin®, Vianex S.A.-Plant C) ensued. After 1.5 months at home, the patient came for a check-up in good health.

**DISCUSSION**

Diagnosis, and especially therapy of clostridial infection is a problem at any level of the health system organization.

The greatest effect in therapy would be achieved by complete exclusion of antibiotic therapy in the patient, in order to allow spontaneous recovery of the intestinal flora and restoring the balance between pathogenic and non-pathogenic strains. Such an approach, usually is not possible in a practice, because, often, these patients have multiple associated infections, systemic infections or are in a critical general health condition, and therefore, treatment with antibiotics is necessary.

According to the recommendations, metronidazole or vancomycin should be administered orally as the first line drug treatment, although, metronidazole may also be administered intravenously, especially in hospitalized patients, in critical condition. According to some authors, possible presence of adynamic ileus in patients during the post-operative course can significantly affect the distribution and absorption of orally administered drug, and therefore, vancomycin enema is often given as an additional therapy [16].

Vancomycin should be included in the treatment of the first relapse of CDI only if there is a return of symptoms of the disease associated with clinical parameters that indicate a severe form of the disease (if the patient has severe leukocytosis, or hypotension and renal failure). Each relapse of the disease should be treated primarily with vancomycin, with long-term gradual dose tapering, or with the use of pulse doses over a long period of time. Some of the authors recommended the following tapering regimen: during the first two weeks of therapy, vancomycin should be administered in a dose of 1 g daily, divided into 4 doses, then 500 mg divided into two doses over the next 7 days, then 125 mg in a single dose for another 7 days. After that, the therapy should be applied in a dose of 125 mg, but first on every other day for a total of 8 days, and then on every third day for another two weeks. In general, there is a number of therapeutic approaches with gradual dose reduction, and further research should confirm the superiority of one of these approaches [17,18]. However, if these treatment regimens do not lead to a cure, treatment with oral rifaximin sometimes suggested [19].

There is small number of studies examining the efficacy of ramoplanin and nitrazoxanide in relapsed CDI. A lower degree of resistance was observed to ramoplanin compared to vancomycin. On the other hand, nitrazoxanid has shown similar efficacy as the drugs used so far for CDI but additional studies need to confirm the safety of its use [20,21]. However these two drugs do not have marketing authorization for treatment of Clostridiocile colitis, yet. In the treatment of recurrent forms, fidaxomicin can be used. Fidaxomicin is more effective than vancomycin in terms of the number of recurrent cases. It has similar properties as vancomycin. Its absorption from the digestive tract is minimal, so the possibility of side effects is low. It also has a minimal bactericidal effect on the remaining microorganisms that are part of the normal intestinal flora [22,23].

Studies have shown that despite the practice of excluding proton pump inhibitors (PPIs) and H2 blockers - from CDI therapy, relapse is only affected by infection-specific drugs [24]. Also, using additional antibiotics in order to control other and systemic infections that are concomitant with CDI, is associated with prolonged duration of diarrhea and a greater number of recurrent forms of CDI [25].

A vaccine that can prevent recurrent forms of CDI has been developed. It is a toxoid vaccine that allows the production of protective antibodies to the toxin Clostridium difficile: toxins A and B. Recent recommendations include using of intravenous immunoglobulins (IVIG) in CDI, which is mainly based on neutralization mediated by antibodies to toxin
A, although antibodies to toxin B have an additive effect [26,27,28]. Up to date, it has not been proven that the use of probiotics can prevent the occurrence of recurrent forms of CDI. Fecal transplantation is one of newer methods used in patients with severe clinical picture and in those in whom all other treatment modalities were ineffective. It can also be used in patients with toxic megacolon within the CDI, who are candidates for surgical treatment. The stool of a healthy donor is inserted through a catheter into the lower or upper part of the digestive tract. In this way, it can stimulate the restoration of the normal flora of the patient’s digestive tract [29].

In patients with CDI-induced megacolon who did not develop additional complications, mortality is about 15%. This mortality increases if the patient develops more severe complications over time, such as ischemia and perforation of the intestinal wall [30].

The mortality of patients with CDI toxic megacolon who were subjected to total colectomy before occurrence of perforation, is significantly lower compared to those who were operated after the large bowel perforation [31,32]. Besides, surgery significantly reduces mortality if performed before development of septic shock [33].

Of course, it is necessary to think about the Oligivie syndrome as differential diagnosis, but Ogilvie syndrome usually does not present with signs of systemic toxicity, with similar CT finding as toxic megacolon [34].

In our patient we combined the use of metronidazole as the first treatment line and vancomycin in patients with severe infection, the main reason is better efficacy compared to the use of only one antibiotic and less chance for resistant on both antibiotics in similar time [34,35].

CONCLUSION

In conclusion, our case shows that in younger patients, who were fit before occurrence of CI. difficile colitis and toxic megacolon, conservative therapy should be tried as long as possible before turning to colectomy, since chances for cure without surgery are considerable. Total colectomy bears significant morbidity by itself, therefore any chances to avoid it without endangering the patient’s life should be taken.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

REFERENCES

1. Cohen SH, Gerding DN, Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile infection in adults: Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infection Control and Hospital Epidemiology. 2010;31:431–455.

2. Sheth SG, LaMont JT. Toxic megacolon. Lancet. 1998. 351(9101):509-13

3. Cohen SH, Gerding DN, Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile infection in adults: Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infection Control and Hospital Epidemiology. 2010;31:431–455.

4. Martin JS, Monaghan TM, Wilcox MH.. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206-16

5. Shivashankar R, Khanna S, Kammer PP. et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466-71.

6. Sartelli M, Malangoni MA, Abu-Zidan FM. et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38.

7. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, MacFadden DR. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520-531

8. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; : 881-891.

9. Dallal RM, Harbrecht BG, Boujoukas AJ. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363-72.

10. Mourelle M, Casellas F, Guarner F, et al. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology. 1995 109(5):1497-502.

11. Sheth SG, LaMont JT. Toxic megacolon. Lancet. 1998 Feb 14. 351(9101):509-13

12. Martin JS, Monaghan TM, Wilcox MH.. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206-16

13. Shivashankar R, Khanna S, Kammer PP. et al.
Clinical factors associated with development of severe-complicated *Clostridium difficile* infection. Clin Gastroenterol Hepatol. 2013;11(11):1466-71

14. Stallmach A. *Clostridium difficile* infection: What is currently available for treatment? Internist (Berl). 2016;57(12):1182-1190

15. Sheikh AAE, Sheikh AB, Shah I, Khair AH, Javed N, Shekhar R. COVID-19 and fulminant *Clostridium difficile* colitis co-infection. EJCRIM 2021

16. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018. 66 (7):987-94

17. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 26(1), 17–25 (2010).

18. Kelly CP, LaMont JT. *Clostridium difficile* - more difficult than ever. N. Engl. J. Med. 359(18), 1932-1940 (2008).

19. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67(13), 1947-1967 (2007).

20. Mushler DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of *Clostridium difficile* colitis. Clin. Infect. Dis. 43(4), 421-427 (2006).

21. Mushler DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in *Clostridium difficile* infection: a randomized, double-blind study. Clin. Infect. Dis. 48(4), e41-e46 (2009).

22. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of *Clostridium difficile* infection. Ann. Pharmacother. 46(2), 219-228 (2012).

23. Cornely OA, Crook DW, Esposito R et al.; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12(4), 281-289 (2012).

24. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection. Arch. Intern. Med. 170(9), 772-778 (2010).

25. Mullaney KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for *Clostridium difficile* infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53(5), 440-447 (2011).

26. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent *Clostridium difficile* infection (CDI). Vaccine 28(4), 965-969 (2010).

27. Kelly CP, Pothoulakis C, Yavva F et al. Anti-*Clostridium difficile* bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of *C. difficile* toxins. Antimicrob. Agents Chemother. 40(2), 373-379 (1996).

28. Warny M, Fatimi A, Bostwick EF et al. Bovine immunoglobulin concentrate-*Clostridium difficile* retains *C difficile* toxin neutralising activity after passage through the human stomach and small intestine. Gut 44(2), 212-217 (1999).

29. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. Clin. Infect. Dis. 53(10), 994-1002 (2011).

30. Cheng YW, Fischer M. Fecal microbiota transplantation: redefining surgical management of refractory *Clostridium difficile* infection. Clin Colon Rectal Surg. 2020 Mar. 33(2):92-7.

31. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005. 22:9

32. Doshi R, Desai J, Shah Y, Dector D, Doshi S. Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States. Intern Emerg Med. 2018 Sep. 13(6):881-7.

33. Ahmed N, Kuo YH. Early colectomy saves lives in toxic megacolon due to *Clostridium difficile* infection. South Med J. 2020 Jul. 113(7):345-9.

34. Lahue B, Davidson DM. Metronidazole and vancomycin outcome for *Clostridium difficile*-associated diarrhea in a US hospital database [Internet]; Abstract presented at: 17th Annual Meeting of the European Congress of Clinical Microbiology and Infectious Disease; 2007 Mar 31 - Apr 04;

35. Thomas KL, Holmes KR, Jackson BR, Go M, Fang JC, Peterson KA. A cost comparison of metronidazole and vancomycin in the treatment of *Clostridium difficile* associated diarrhea [abstract] Am J Gastroenterol. 2007;102 Suppl 2:S268.
Toksični megakolon posle iracionalne primene antibiotika u lečenju trudnice sa Covid-om 19: prikaz slučaja

Mladen M. Maksić, Andela Ž. Đokić, Nataša D. Zdravković, Biljana N. Milojković - Kicevska, Radiša H. Vojinović, Tijana B. Veljković, Svetlana S. Popović - Matović, Slobodan M. Janković

1 Univerzitetski klinički centar Kragujevac, Kragujevac, Srbija
2 Fakultet medicinskih nauka, Univerzitet u Kragujevcu, Kragujevac, Srbija

KRATAK SADRŽAJ

Uvod: Optimalno upravljanje toksičnim megakolonom kao posledicom Cl. difficile kolitis je još uvek predmet kontroverzi, kao i vreme kada su dostupni terapijski modaliteti. U ovom članku izveštavamo o slučaju teškog kolitisa C. difficile povezanog sa toksičnim megakolonom kod trudnice sa Covid-om 19, koja je uspešno lečena konzervativno.

Prikaz slučaja: Trudnica stara 33 godine zarazila se SARS-CoV-2 u 32. nedelji trudnoće. Primljena je u regionalnu bolnicu i intenzivno lečena antibioticima širokog spektra. Nakon porođaja razvila je teški oblik Cl. difficile kolitis sa toksičnim megakolonom. I pored teške kliničke slike, pacijent je lečen konzervativno, visokim početnim oralnim dozama vankomicina, uz naknadno smanjivanje. Ishod lečenja je bio potpuni oporavak i potpuno su vracene funkcije debelog creva.

Zaključak: U zaključku, naš slučaj pokazuje da kod mladih pacijenata, koji su bili u formi pre pojave Cl. difficile kolitis sa toksičnim megakolonom, konzervativnu terapiju treba pokušavati što je duže moguće pre nego što se pređe na kolektomiju, pošto su šanse za izlečenje bez operacije znatne.

Ključne reči: Cl. difficile kolitis, toksični megakolon, vankomicin

Received: May 16, 2022
Accepted: June 29, 2022